Prolia is Amgen’s brand of denosumab for osteoporosis. It is not a pill you pick up and take home. A health professional injects one 60 mg prefilled syringe under the skin, and the schedule is one shot every six months for as long as you stay on treatment.

That makes Prolia pricing a two-part problem for anyone paying cash. There is the syringe itself, which is expensive and roughly fixed, and there is whatever the clinic charges to put it in your arm, which is negotiable. The other thing that changed recently is competition: denosumab biosimilars are now on the U.S. market and CMS is publishing prices for them, which gives cash payers a real lever for the first time. Everything below was researched September 3, 2026.

What Does Prolia Cost Without Insurance?

Four independent 2026 sources price the drug, and they land within about 7% of each other. Medicare’s Part B payment limit file for July 1 through September 30, 2026 pays $30.101 per milligram under HCPCS code J0897, which is $1,806.06 for a 60 mg dose. CMS’s National Average Drug Acquisition Cost survey, which measures what pharmacies actually pay, listed the Prolia syringe at $1,863.72 effective August 19, 2026. Drugs.com quotes a cash price of $1,894.78. Amgen’s own list-pricing document, accurate as of January 7, 2026, states a wholesale acquisition cost of $1,931.69 per syringe.

Prolia (denosumab) 60 mg cost itemLowTypicalHigh
One syringe, drug only$1,806.06$1,863.72$1,931.69
One year of therapy (2 doses), drug only$3,612.12$3,727.44$3,863.38
Denosumab biosimilar, one syringe (CMS NADAC)$812.84$1,584.71$1,740.45
Injection administration, CPT 96372, Medicare national rate$15.36$15.36$15.36
Medicare Part B coinsurance per dose (17.326%)$312.92$312.92$312.92
Amgen SupportPlus co-pay program (commercial insurance required)$0$0$0

For a reality check, CMS’s Medicare Part B spending data for 2024 shows average Medicare spending of $1,815.03 per Prolia claim and $3,469.18 per beneficiary for the year, across 700,724 beneficiaries and $2.43 billion in total spending. Those are Medicare-allowed amounts rather than cash prices, but they confirm the per-dose number is real rather than a sticker nobody pays.

The injection fee is a separate bill

Somebody has to give you the shot, and that is billed under CPT 96372, the code for a therapeutic subcutaneous or intramuscular injection. CMS’s July 2026 relative value file assigns that code 0.46 total non-facility relative value units, which at the $33.4009 conversion factor comes to about $15.36 nationally in a physician office.

That is what Medicare pays, not what a self-pay clinic charges. Most practices will bill an office visit for the same encounter, and a hospital outpatient department will usually charge more than a physician office for identical work. Ask for one itemized cash quote covering the drug, the injection, and the visit before you schedule, because the drug price is the part you cannot move much and the other two are the parts you can.

What Drives the Price

Biosimilar competition, finally. FDA has now approved 19 denosumab biosimilars referencing Prolia. Four of them carry real prices in CMS’s September 2026 data: Bildyos from Organon at $812.84 per 60 mg syringe in NADAC, Jubbonti from Sandoz at $1,537.25, Stoboclo from Celltrion at $1,584.71, and Conexxence from Fresenius Kabi at $1,740.45. Prolia sits above all of them at $1,863.72. The other approved biosimilars, including Ospomyv and Xbryk from Samsung Bioepis, do not yet appear in either the CMS acquisition-cost file or the July 2026 Part B crosswalk, so approval and availability are not the same thing.

Whether it is billed to the medical benefit or the pharmacy benefit. Prolia moves both ways. It is a classic buy-and-bill Part B drug when a clinic buys the syringe and injects it, and it also moves through specialty pharmacies under a drug benefit. That is why it has both a Medicare Part B payment limit and a retail acquisition cost, and why the price you are quoted depends on which door you walk through.

Where you get it. A primary care office, a rheumatology practice, a hospital outpatient clinic and an infusion center will not quote the same total for the same injection. Hospital-based departments are usually the most expensive setting.

The twice-a-year schedule. Prolia is dosed every six months, which means a year of therapy is two syringes, not twelve doses. That is the whole cost structure. Compared with a monthly injectable it looks cheap per year, and compared with a generic oral bisphosphonate it does not.

No direct-to-patient cash program. Amgen’s SupportPlus co-pay program is the main affordability tool attached to Prolia, and it requires commercial insurance. Prolia.com directs uninsured patients to nonprofit foundations rather than to a published cash price.

Cash Price vs. Insurance

This is a drug where insurance wins decisively when you have it, and it is worth saying that plainly. Amgen reports that 100% of Medicare Part B patients have access to Prolia as initial therapy with no step edit or prior authorization, and that 96% of Medicare Part D patients have access. Under traditional Medicare Part B, the July 2026 CMS file sets the beneficiary coinsurance for J0897 at an inflation-adjusted 17.326% rather than the standard 20%, which is about $312.92 on a $1,806.06 allowed amount. A supplemental Medigap or retiree plan often brings that to $0.

Commercially insured patients can use the Amgen SupportPlus Co-Pay Program, which Amgen says can bring out-of-pocket cost to as little as $0 per dose. Eligibility criteria and annual program maximums apply, and the program is not open to uninsured patients or to anyone on Medicare, Medicaid or another federal program. Drugs.com also lists a rebate route through the same program for commercially insured patients who already paid.

If you are uninsured, none of that helps you. There is no published cash price for Prolia the way there is for some direct-to-patient injectables, and the co-pay program is closed to you by design. The biosimilars are the only real price pressure available to a cash payer.

How to Pay Less

  1. Ask the clinic to use a denosumab biosimilar and ask which one. This is the single biggest lever on this page. The spread between Bildyos at $812.84 and Prolia at $1,863.72 in the same CMS acquisition file is more than $1,000 per syringe, or more than $2,000 a year. Clinics stock what their group purchasing contract favors, so the answer may be no, but the question costs nothing.

  2. Get the quote broken into three numbers before you book. Drug, injection administration, and office visit. Our fair price checker helps you sanity-check the visit portion, and a standard cash-pay doctor visit runs a lot less than most people expect.

  3. Choose a physician office over a hospital outpatient department. Same syringe, same billing code, different price structure. If a health system is your only option, our guide to hospital price transparency explains how to pull that facility’s posted cash rate before the appointment.

  4. Ask for the self-pay discount in writing. Practices that buy and bill expensive drugs almost always have a prompt-pay or self-pay policy and rarely volunteer it. Our guide to negotiating medical bills covers the script, and hospital charity care applies if a hospital is doing the billing.

  5. Check the independent charitable foundations. Osteoporosis funds at organizations like the HealthWell Foundation and the PAN Foundation can cover cost sharing for people who do not qualify for a manufacturer program. Funds open and close through the year, so apply the moment one opens.

  6. Price the alternatives honestly. Generic oral alendronate and the yearly Reclast infusion are far cheaper per year than any denosumab, and the anabolic injectables Forteo and Tymlos are far more expensive. That is a conversation for your prescriber, but knowing the numbers first changes it.

  7. Do not let the monitoring costs surprise you. A free or sliding-scale clinic can handle the prescribing visits, and a DEXA bone density scan has its own cash price worth checking separately.

Bottom Line

Budget roughly $1,800 to $1,950 for each Prolia syringe as of September 2026, plus whatever the clinic charges to inject it, which Medicare prices at about $15 but a self-pay practice will set higher. Two shots a year puts the drug cost around $3,600 to $3,900 annually.

The number that actually matters for a cash payer is the biosimilar spread. CMS’s own acquisition-cost file shows four marketed denosumab biosimilars priced from $812.84 to $1,740.45 per syringe against Prolia’s $1,863.72, which means the same molecule can cost less than half as much depending entirely on what your clinic pulls out of the refrigerator. If you are comparing the whole osteoporosis shelf, Evenity is the expensive twelve-month option and hormone therapy has its own separate pricing story.